TICKERNERD
Menu
CYTKCYTKHealthcare · Biotechnology

CYTK Stock Forecast: Cytokinetics, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$77
+0.26% on the day

The 22 Wall Street analysts covering Cytokinetics, Inc. hold a median 12-month price target of $108 — +39.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 53 of 100 as at 22 Aug 2026 — in the upper half.

Market cap
$10.7B
Ticker Nerd rank
53 / 100
Median analyst target
$108
Analysts covering
22
Revenue$28.6M−57.1% y/y
Operating income−$179.2M
Net income−$198.8M
Free cash flow−$164.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.5%
1M
−4.6%
YTD
+21.2%
1Y
+100.9%
From 52W high
−11.7%
From 52W low
+118.1%
$35
$87
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CYTK stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Cytokinetics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
53 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
90
Revisions
87
Volatility
77
Value
70
Accruals
46
Quality
44
Growth
32
Size
15
Issuance
10

Momentum (90): The shares have been drifting up relative to others.

Issuance (10): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CYTK stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CYTK, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$40$60$80$100$120$140$160Oct 25Jan 26Apr 26Jul 26CYTKHigh $146Median $108Low $85

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says22 analysts
20 Buy2 Hold0 Sell
Low $85Median $108High $146

The green dot is the last close — the median target sits +39.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
13 Aug 2026BarclaysMaintainsOverweight$95 → $110
13 Aug 2026JP MorganMaintainsOverweight$97 → $103
10 Aug 2026Truist SecuritiesMaintainsBuy$106 → $112
7 Aug 2026CitizensMaintainsMarket Outperform$105 → $110
7 Aug 2026NeedhamMaintainsBuy$102 → $112
7 Aug 2026RBC CapitalMaintainsOutperform$117 → $112
7 July 2026RBC CapitalMaintainsOutperform$119 → $117
7 July 2026RBC CapitalMaintainsOutperform—
29 June 2026UBSUpgradeBuy—
24 June 2026MizuhoMaintainsOutperform—
17 June 2026NeedhamReiteratesBuy—
19 May 2026CitigroupInitiatesBuy—
12 May 2026JP MorganMaintainsOverweight—
11 May 2026HC Wainwright & Co.MaintainsBuy—
7 May 2026Wells FargoMaintainsOverweight—
6 May 2026Morgan StanleyMaintainsOverweight—
6 May 2026RBC CapitalMaintainsOutperform—
6 May 2026StifelMaintainsBuy—
5 May 2026NeedhamMaintainsBuy—
10 Apr 2026Wells FargoInitiatesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CYTK appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CYTK vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Aug 2026, Cytokinetics, Inc. returned +100.9% against +19.6% for the S&P 500, dividends included.

CYTK vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200Oct 25Jan 26Apr 26Jul 26CYTKS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CYTK analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
6
Analysts cutting
0
Fundamentals

Cytokinetics, Inc. (CYTK) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−11.8×

Cheaper than 93% of US stocks

Price / sales
157.9×

Cheaper than 3% of US stocks

Price / book
−58.6×

Cheaper than 99% of US stocks

EV / EBITDA
−15.7×

Cheaper than 87% of US stocks

Growth & margins
Revenue growth (YoY)
−57.1%

Higher than 5% of US stocks

Earnings growth (YoY)
−57.1%

Higher than 9% of US stocks

Gross margin
80.5%

Higher than 91% of US stocks

Operating margin
−626.0%

Higher than 7% of US stocks

Net margin
−372.5%

Higher than 1% of US stocks

Returns & dividend
Return on equity
119.0%

Higher than 97% of US stocks

Return on assets
−28.1%

Higher than 15% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Cytokinetics, Inc. (CYTK) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Cytokinetics, Inc. has a market value of $10.7B and an enterprise value of $10.9B.

  • Revenue in the twelve months to 30 June 2026: $67.7M. The latest quarter shrank 57.1% year on year.

  • Net income over the same four quarters: −$894.0M, a −1321.1% net margin.

  • Diluted earnings per share, trailing twelve months: $−7.22.

  • Free cash flow in the twelve months to 30 June 2026: −$580.7M.

  • Shares outstanding: 135.8M.

  • Trailing P/E: −11.8×; forward P/E: −17.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Cytokinetics, Inc. employs 673 people — $101K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 25 Aug 2026

Data provided by Twelve Data

Peers

CYTK vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CYTKCytokinetics, Inc.$10.7B
53
AXSMAxsome Therapeutics, Inc.$10.7B
74
SMMTSummit Therapeutics, Inc.$10.5B
19
PRAXPraxis Precision Medicines, Inc.$10.3B
43
KRYSKrystal Biotech, Inc.$10.3B
79
APGEApogee Therapeutics, Inc.$10.2B
36
TECHBio-Techne Corp.$11.3B
94

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Cytokinetics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CYTK news & analysis

Insider Transaction: Cytokinetics CEO Robert Blum Sells 7,500 Shares for $575,700

The Motley Fool · 22 Aug 2026neutral

Cytokinetics CEO Robert Blum disposed of 7,500 shares in a transaction valued at $575,700, reducing his total insider equity holdings by 2%. The report notes the sale as a reduction in his stake in the company.

Why it matters — Insider sales by the CEO can draw attention from CYTK watchers as a potential signal about management's view of the stock, though the 2% reduction is relatively modest in scope.

Cytokinetics Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026

GlobeNewsWire · 20 Aug 2026positive

Cytokinetics announced upcoming presentations at the European Society of Cardiology (ESC) Congress 2026, including a Hot Line presentation of primary results from the ACACIA-HCM trial. The presentation will elaborate on positive topline results in patients with non-obstructive hypertrophic cardiomyopathy.

Why it matters — This signals a key upcoming data milestone for ACACIA-HCM, a program that could expand Cytokinetics' reach into non-obstructive hypertrophic cardiomyopathy and warrants attention from CYTK watchers.

Cytokinetics Gains 20.5% YTD: Buy, Sell or Hold the Stock?

Zacks Investment Research · 19 Aug 2026positive

Cytokinetics' stock has gained 20.5% year-to-date. The article discusses the company's prospects, noting that early launch momentum for Myqorzo and global expansion could boost the company, while pipeline progress may widen its growth opportunity.

Why it matters — CYTK watchers would care because the piece highlights Myqorzo's commercial launch traction and pipeline development as potential growth drivers for the company.

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 18 Aug 2026neutral

Cytokinetics announced that on August 14, 2026, it granted stock options covering an aggregate of 27,565 shares of common stock and 18,273 restricted stock units (RSUs), to be settled in common stock upon vesting, to 12 employees who joined the company in July and August 2026. The grants serve as a material inducement to their employment under Nasdaq Listing Rule 5635(c)(4).

Why it matters — This disclosure shows Cytokinetics is using equity-based incentives to attract and retain newly hired personnel, which could be of interest to shareholders monitoring the company's compensation practices and workforce growth.

CYTK Q2 Earnings Top Estimates, Myqorzo Uptake Strong

Zacks Investment Research · 7 Aug 2026neutral

Cytokinetics beat Q2 revenue estimates as its drug Myqorzo gained traction, though higher launch costs and the absence of milestone payments weighed on results.

Why it matters — CYTK watchers would care because the report highlights both the commercial progress of Myqorzo and the cost pressures affecting the company's financial results.

FAQ

Frequently asked questions about CYTK stock

What is the CYTK stock price forecast for 2026-2027?

The 22 Wall Street analysts covering Cytokinetics, Inc. have a median 12-month price target of $108, with estimates ranging from $85 to $146. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CYTK stock a buy right now?

Of the 22 analysts covering Cytokinetics, Inc., 20 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cytokinetics, Inc. 53 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CYTK?

As at 22 Aug 2026, Cytokinetics, Inc. ranks 53 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (90 of 100).

Will CYTK stock go up?

No one can know that. What the data says: the median 12-month target from 22 analysts implies +39.5% from the last close, and Ticker Nerd's factor model ranks Cytokinetics, Inc. 53 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CYTK stock forecast for 2030?

No analyst covering Cytokinetics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CYTK are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $85 to $146 over the next 12 months.

How has CYTK stock performed over the past year?

Cytokinetics, Inc. returned +100.9% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Cytokinetics, Inc. do?

Cytokinetics, Incorporated is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors. These small-molecule therapies target debilitating diseases where muscle performance is compromised or declining, including amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, hypertrophic cardiomyopathy, and chronic obstructive pulmonary disease.

What is the latest news on CYTK?

The most recent item we track (The Motley Fool, 22 Aug 2026): "Insider Transaction: Cytokinetics CEO Robert Blum Sells 7,500 Shares for $575,700". Cytokinetics CEO Robert Blum disposed of 7,500 shares in a transaction valued at $575,700, reducing his total insider equity holdings by 2%. The report notes the sale as a reduction in his stake in the company.

Company

About Cytokinetics, Inc.

Cytokinetics, Incorporated is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors. These small-molecule therapies target debilitating diseases where muscle performance is compromised or declining, including amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, hypertrophic cardiomyopathy, and chronic obstructive pulmonary disease. By specifically engineering compounds to enhance muscle function and contractility, Cytokinetics addresses impaired muscle function in cardiovascular and neuromuscular conditions. The company advances muscle-directed investigational medicines aimed at improving health outcomes for patients with serious diseases of cardiac and skeletal muscle dysfunction. Founded in 1997 and headquartered in South San Francisco, California, Cytokinetics leverages expertise in muscle biology to build a pipeline of sarcomere-directed therapies, positioning it as a key player in specialized biopharmaceutical innovation for muscle-related disorders.

CEO Mr. Robert I. Blum · 673 employees · United States · https://www.cytokinetics.com